Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Pasta

Showing results (41-50 of 98) with videos related to

Pageof 10
Sort By:
Pediatric Pulmonology|October 25, 2017
Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen changeDonald R VanDevanter, Marcia L Craib, David J Pasta, et al.
Annals of the American Thoracic Society|November 16, 2017
Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary ExacerbationsMichael S Schechter, Donald R VanDevanter, David J Pasta, et al.
The Journal of Pediatrics|September 22, 2015
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung FunctionWayne J Morgan, Donald R VanDevanter, David J Pasta, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 14, 2012
Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sampleAlexandra L Quittner, Gregory S Sawicki, Ann McMullen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 29, 2013
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomesGregory S Sawicki, Clement L Ren, Michael W Konstan, et al.
Annals of the American Thoracic Society|March 22, 2017
Relationship of Antibiotic Treatment to Recovery after Acute FEV<sub>1</sub> Decline in Children with Cystic FibrosisWayne J Morgan, Jeffrey S Wagener, David J Pasta, et al.
Pediatric Pulmonology|April 25, 2017
Risk factors for mortality before age 18 years in cystic fibrosisSusanna A McColley, Michael S Schechter, Wayne J Morgan, et al.
Managed Care Interface|March 16, 2005
Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURENatalia Sadetsky, Deborah P Lubeck, David M Latini, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosisJeffrey S Wagener, Michael J Williams, Stefanie J Millar, et al.
Sleep Medicine|July 11, 2021
Assessing the impact of sodium oxybate treatment on functioning, productivity, and health-related quality of life in patients with narcolepsy: findings from the Nexus Narcolepsy Registry (waves 1-4)Michael J Thorpy, Maurice M Ohayon, Ginger Carls, et al.
Pageof 10

Showing results (41-50 of 98) with videos related to

Sort By:
Pageof 10
Pediatric Pulmonology|October 25, 2017
Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen changeDonald R VanDevanter, Marcia L Craib, David J Pasta, et al.
Annals of the American Thoracic Society|November 16, 2017
Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary ExacerbationsMichael S Schechter, Donald R VanDevanter, David J Pasta, et al.
The Journal of Pediatrics|September 22, 2015
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung FunctionWayne J Morgan, Donald R VanDevanter, David J Pasta, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 14, 2012
Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sampleAlexandra L Quittner, Gregory S Sawicki, Ann McMullen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 29, 2013
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomesGregory S Sawicki, Clement L Ren, Michael W Konstan, et al.
Annals of the American Thoracic Society|March 22, 2017
Relationship of Antibiotic Treatment to Recovery after Acute FEV<sub>1</sub> Decline in Children with Cystic FibrosisWayne J Morgan, Jeffrey S Wagener, David J Pasta, et al.
Pediatric Pulmonology|April 25, 2017
Risk factors for mortality before age 18 years in cystic fibrosisSusanna A McColley, Michael S Schechter, Wayne J Morgan, et al.
Managed Care Interface|March 16, 2005
Demographics, insurance coverage, and utilization of medical services in newly diagnosed prostate cancer: data from caPSURENatalia Sadetsky, Deborah P Lubeck, David M Latini, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
Pulmonary exacerbations and acute declines in lung function in patients with cystic fibrosisJeffrey S Wagener, Michael J Williams, Stefanie J Millar, et al.
Sleep Medicine|July 11, 2021
Assessing the impact of sodium oxybate treatment on functioning, productivity, and health-related quality of life in patients with narcolepsy: findings from the Nexus Narcolepsy Registry (waves 1-4)Michael J Thorpy, Maurice M Ohayon, Ginger Carls, et al.
Pageof 10